VNDA
Vanda Pharmaceuticals Inc.
$5.94
-1.49%
$357.2M
No data for this timeframe.
Vol
Market Cap$357.2M
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (82%)
Inst. Holders8 funds
Inst. Value$84.3M
Inst. Activity2 buys / 0 sells
Insider Activity0B / 3S
Insider Net $-$1.9M
Reddit Sentiment69° Warm
SEC Reports1
Recent Activity
Dec 12, 2026
fda_pdufa
PDUFA: VNDA — imsidolimab in Generalized Pustular Psoriasis — 2026-12-12
FDA target action date 2026-12-12 for VNDA (Vanda Pharmaceuticals Inc.). Drug: imsidolimab. Indicati
Jun 4, 2026
Insider
McGuire Daniel Patrick sold 80,000 shares
SVP, GC and Secretary @ $0.00 ($0.00)
Jun 4, 2026
Insider
DUGAN RICHARD W sold 41,600 shares
Director @ $0.00 ($0.00)
Jun 4, 2026
Insider
Chrousos Phaedra sold 41,600 shares
Director @ $0.00 ($0.00)
May 6, 2026
SEC
Vanda Pharmaceuticals reported Q1 2026 revenue of $51.7M (+3% YoY), in line with modest growth, but EPS of -$0.82 missed
8-K — Impact 6/10
Inst.
TWO SIGMA INVESTMENTS, LP — ADD
978,990 shares ($8.6M)
Inst.
WELLS FARGO & COMPANY/MN — ADD
68,743 shares ($606.3K)
Mar 30, 2026
Event
1:23-cv-00152 Vanda Pharmaceuticals Inc. v. Teva Pharmaceuticals U.S.A., Inc.
Court ruling from United States District Court for the District of Delaware. Docket: N/A
Price Targets
$14.90
+143.5% upside
Strong Buy
Current $6.12
Low $7.50
Median $17.00
High $21.00
5 analysts
$7.50
$21.00
Analyst Ratings
2Strong Buy
7Buy
2Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 11, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| Mar 5, 2026 | Truist Securities | INITIATE | Buy |
| Feb 23, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| Jan 5, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| Dec 31, 2025 | B. Riley Securities | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.61 ▼ -5.4% | $-0.71 — $-0.49 | -32% YoY | 5 |
| Next Q | $-0.52 ▲ +1.1% | $-0.60 — $-0.36 | -38% YoY | 5 |
| Current FY | $-2.31 ▼ -2.5% | $-2.68 — $-1.98 | 38% YoY | 5 |
| Next FY | $-0.88 ▼ -25.7% | $-1.32 — $-0.36 | 62% YoY | 5 |
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $32.9M | — |
| RENAISSANCE TECHNOLOGIES LLC | $29.8M | — |
| TWO SIGMA INVESTMENTS, LP | $8.6M | ADD |
| MORGAN STANLEY | $5.2M | TRIM |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $4.4M | NEW |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 4, 2026 | McGuire Daniel | A | $0.00 |
| Jun 4, 2026 | DUGAN RICHARD | A | $0.00 |
| Jun 4, 2026 | Chrousos Phaedra | A | $0.00 |
| Jun 4, 2026 | Duncan Charles | A | $0.00 |
| Jun 4, 2026 | Ward Anne | A | $0.00 |
Reddit Sentiment
69°
Warm
Bearish
Neutral
Bullish
8 institutional holders with $84.3M total value (9,557,766 shares) as of 2025-Q4. Top holders: VANGUARD, RENAISSANCE, TWO. Net buying activity: 2 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 3,731,851 | $32.9M | 39.0% | — |
| 2 | RENAISSANCE TECHNOLOGIES LLC | 3,380,961 | $29.8M | 35.4% | — |
| 3 | TWO SIGMA INVESTMENTS, LP | 978,990 | $8.6M | 10.2% | ADD +47.8% |
| 4 | MORGAN STANLEY | 593,023 | $5.2M | 6.2% | TRIM -29.2% |
| 5 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 500,515 | $4.4M | 5.2% | NEW |
| 6 | FMR LLC | 222,269 | $2.0M | 2.3% | — |
| 7 | BANK OF AMERICA CORP /DE/ | 81,414 | $718.1K | 0.9% | TRIM -28.8% |
| 8 | WELLS FARGO & COMPANY/MN | 68,743 | $606.3K | 0.7% | ADD +40.3% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| TWO SIGMA INVESTMENTS, LP | ADD | 662,305 | 978,990 | +47.8% | $8.6M | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 48,994 | 68,743 | +40.3% | $606.3K | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | ADD | 526,866 | 662,305 | +25.7% | $3.3M | 2025-Q3 |
| MORGAN STANLEY | TRIM | 900,477 | 637,499 | -29.2% | $3.2M | 2025-Q3 |
| UBS Group AG | ADD | 69,844 | 126,116 | +80.6% | $629.3K | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | TRIM | 149,471 | 106,436 | -28.8% | $531.1K | 2025-Q3 |
| NORGES BANK | EXIT | 115,000 | 0 | -100.0% | $0.00 | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 175,632 | 526,866 | +200.0% | $2.5M | 2025-Q2 |
| NORGES BANK | NEW | — | 115,000 | — | $542.8K | 2025-Q2 |
| MORGAN STANLEY | TRIM | 1,340,503 | 916,720 | -31.6% | $4.2M | 2025-Q1 |
| UBS Group AG | TRIM | 229,937 | 87,586 | -61.9% | $402.0K | 2025-Q1 |
| NORGES BANK | EXIT | 115,000 | 0 | -100.0% | $0.00 | 2025-Q1 |
| MORGAN STANLEY | DOUBLED | 616,421 | 1,340,503 | +117.5% | $6.4M | 2024-Q4 |
| CITADEL ADVISORS LLC | ADD | 215,035 | 404,485 | +88.1% | $1.9M | 2024-Q4 |
| UBS Group AG | ADD | 150,681 | 229,937 | +52.6% | $1.1M | 2024-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 26,170 | 33,509 | +28.0% | $160.5K | 2024-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 596,210 | — | $2.8M | 2024-Q3 |
9 unique insiders with 3 transactions. Net insider value: -$1.9M ($0.00 bought, $1.9M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 4, 2026 | McGuire Daniel Patrick | SVP, GC and Secretary | A | 80,000 | $0.00 | $0.00 |
| Jun 4, 2026 | DUGAN RICHARD W | Director | A | 41,600 | $0.00 | $0.00 |
| Jun 4, 2026 | Chrousos Phaedra | Director | A | 41,600 | $0.00 | $0.00 |
| Jun 4, 2026 | Duncan Charles Cliff | Director | A | 41,600 | $0.00 | $0.00 |
| Jun 4, 2026 | Ward Anne Sempowski | Director | A | 41,600 | $0.00 | $0.00 |
| Jun 4, 2026 | Honore Tage | Director | A | 41,600 | $0.00 | $0.00 |
| Jun 4, 2026 | Mitchell Stephen Ray | Director | A | 41,600 | $0.00 | $0.00 |
| May 18, 2026 | Mitchell Stephen Ray | Director | G | 25,836 | $0.00 | $0.00 |
| Apr 22, 2026 | Duncan Charles Cliff | Director | A | 57,101 | $0.00 | $0.00 |
| Mar 2, 2026 | Williams Timothy | SVP & General Counsel | SELL | 42,434 | $8.27 | $350.8K |
| Mar 2, 2026 | Polymeropoulos Mihael Hristos | President and CEO | SELL | 156,235 | $8.17 | $1.3M |
| Feb 23, 2026 | Honore Tage | Director | SELL | 30,000 | $8.03 | $240.9K |
1 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 1 mixed, 0 neutral. Avg impact: 6.0/10.
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Strong Buy (82% buy). Based on 11 analysts: 2 strong buy, 7 buy, 2 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$14.90 mean target
+143.5% upside
Strong Buy (1.40)
$7.50 Low
$21.00 High
| Metric | Value |
|---|---|
| Current Price | $6.12 |
| Target Low | $7.50 |
| Target Mean | $14.90 |
| Target Median | $17.00 |
| Target High | $21.00 |
| # Analysts | 5 |
| Recommendation | Strong Buy (1.40) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.61 | $-0.71 | $-0.49 | -31.7% | -5.4% | 1↑ 4↓ | $0.1B | 17.5% | 5 |
| Next Q 2026-09-30 |
$-0.52 | $-0.60 | $-0.36 | -37.9% | +1.1% | 3↑ 2↓ | $0.1B | 23.1% | 5 |
| Current FY 2026-12-31 |
$-2.31 | $-2.68 | $-1.98 | 38.1% | -2.5% | 3↑ 2↓ | $0.3B | 21.6% | 5 |
| Next FY 2027-12-31 |
$-0.88 | $-1.32 | $-0.36 | 62.0% | -25.7% | 1↑ 3↓ | $0.4B | 35.6% | 5 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.606 | |
| 7d ago | $-0.606 | |
| 30d ago | $-0.575 | -0.031 |
| 60d ago | $-0.566 | -0.040 |
| 90d ago | $-0.566 | -0.040 |
4 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 1 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 11, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Mar 5, 2026 | Truist Securities | INITIATE | — | Buy |
| Feb 23, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Jan 5, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Dec 31, 2025 | B. Riley Securities | MAINTAIN | Buy | Buy |
| Dec 31, 2025 | Jefferies | MAINTAIN | Hold | Hold |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 7 | 2 | 0 | 0 | 82% | |
| May 1, 2026 | 2 | 7 | 2 | 0 | 0 | 82% | |
| Apr 1, 2026 | 2 | 7 | 2 | 0 | 0 | 82% | |
| Mar 1, 2026 | 2 | 6 | 2 | 0 | 0 | 80% | |
| Feb 1, 2026 | 2 | 6 | 2 | 0 | 0 | 80% | |
| Jan 1, 2026 | 2 | 6 | 2 | 0 | 0 | 80% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
69°
Warm
Bearish
Neutral
Bullish
4 mentions
3 bullish
0 bearish
2 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Feb 22, 2026 | 3 | 64° Warm | 2 | 0 | 3 |
| Feb 21, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
Recent Reddit Threads
Why I'll be buying VNDA on Monday morning
▲ 25
💬 30
⚡ 0.7
Why I’ll be buying VNDA on Monday
▲ 1
💬 1
⚡ 0.0
Why I’ll be buying VNDA on Monday
▲ 1
💬 1
⚡ 0.0
$VNDA - Why it will be a big mover starting Monday PM
▲ 29
💬 24
⚡ 0.7
$vnda could be the buy
▲ 1
💬 0
⚡ 0.0
Dec 12, 2026
fda_pdufa
PDUFA: VNDA — imsidolimab in Generalized Pustular Psoriasis — 2026-12-12
FDA target action date 2026-12-12 for VNDA (Vanda Pharmaceuticals Inc.). Drug: imsidolimab. Indication: Generalized Pustular Psoriasis. PDUFA target a
Jun 3, 2026
Clinical Trial
Safety, Tolerability and Efficacy of Trichostatin A in Patients With Mild to Severe Onychomycosis
Phase Phase 2 — ACTIVE_NOT_RECRUITING
Jun 3, 2026
clinical_trial_readout
T-90d Trial Readout: Trichostatin A (Phase 2)
Trial: Safety, Tolerability and Efficacy of Trichostatin A in Patients With Mild to Severe Onychomycosis
Sponsor: Vanda Pharmaceuticals
Phase: Phase 2
May 27, 2026
short_volume
Short Volume: VNDA — 56.3% short (0.3M / 0.6M)
Short: 327,320 | Exempt: 6,056 | TRF Vol: 581,435 | Short Ratio: 56.3% | Off-exchange volume (dark pool + OTC)
May 20, 2026
drug_approval
EMA: Human medicines European public assessment report (EPAR): Iloperidone Vanda Pharmaceuticals, iloperidone, Status: Opinion
Human medicines European public assessment report (EPAR): Iloperidone Vanda Pharmaceuticals, iloperidone, Status: Opinion
May 18, 2026
short_volume
Short Volume: VNDA — 59.8% short (0.3M / 0.5M)
Short: 314,708 | Exempt: 108 | TRF Vol: 525,900 | Short Ratio: 59.8% | Off-exchange volume (dark pool + OTC)
May 15, 2026
short_volume
Short Volume: VNDA — 69.8% short (0.4M / 0.6M)
Short: 398,626 | Exempt: 8,066 | TRF Vol: 570,697 | Short Ratio: 69.8% | Off-exchange volume (dark pool + OTC)
May 7, 2026
short_volume
Short Volume: VNDA — 56.6% short (0.6M / 1.1M)
Short: 641,788 | Exempt: 60,385 | TRF Vol: 1,134,475 | Short Ratio: 56.6% | Off-exchange volume (dark pool + OTC)
May 6, 2026
earnings_calendar
VNDA Q1 2026 Earnings Scheduled — 2026-05-06
May 5, 2026
earnings_calendar
VNDA Q1 2026 Earnings Scheduled — 2026-05-05
Apr 23, 2026
short_volume
Short Volume: VNDA — 57.8% short (0.4M / 0.6M)
Short: 357,728 | Exempt: 346 | TRF Vol: 619,350 | Short Ratio: 57.8% | Off-exchange volume (dark pool + OTC)
Apr 1, 2026
Clinical Trial
Study to Evaluate the Long-Term Safety and Efficacy of Imsidolimab (ANB019) in the Treatment of Subjects With GPP
Phase Phase 3 — TERMINATED
Mar 30, 2026
Enforcement
1:23-cv-00152 Vanda Pharmaceuticals Inc. v. Teva Pharmaceuticals U.S.A., Inc.
Court ruling from United States District Court for the District of Delaware. Docket: N/A
Feb 21, 2026
fda_pdufa
PDUFA: VNDA — Bysanti in bipolar I disorder and schizophrenia — 2026-02-21
FDA target action date 2026-02-21 for VNDA (Vanda Pharmaceuticals Inc.). Drug: Bysanti. Indication: bipolar I disorder and schizophrenia. PDUFA target
Jan 7, 2026
fda_pdufa
PDUFA: VNDA — HETLIOZ in jet lag disorder — 2026-01-07
FDA target action date 2026-01-07 for VNDA (Vanda Pharmaceuticals Inc.). Drug: HETLIOZ. Indication: jet lag disorder. FDA expedited re-review of sNDA
Dec 30, 2025
fda_pdufa
PDUFA: VNDA — tradipitant in motion sickness — 2025-12-30
FDA target action date 2025-12-30 for VNDA (Vanda Pharmaceuticals Inc.). Drug: tradipitant. Indication: motion sickness. PDUFA target action date for